Lifecore Biomedical is cutting jobs for 46 full-time employees, 9% of the company’s workforce, amid ongoing challenges including tens of millions of dollars in losses last year.
Chaska-based Lifecore, which makes injectable pharmaceuticals, disclosed the layoffs in a filing with the U.S. Securities and Exchange Commission (SEC) Friday, citing the move as “part of an initiative to strategically optimize the company’s cost structure.”
The company indicated it would pay $1 million in severance benefits. A Lifecore representative was not reachable for comment.
Paul Josephs became Lifecore’s new CEO in May following the retirement of James Hall.
In March, Lifecore filed a long-delayed annual financial report for its fiscal year ending May 28, 2023. The document included financial restatements of the company’s 2021 and 2022 fiscal years. NASDAQ notified the company in February about a possible delisting due to delays in the financial filings.
Lifecore disclosed at the time the SEC’s Chicago Regional Office issued a subpoena related to the restatements.